TECHNOLOGY ASSIGNMENT AGREEMENTTechnology Assignment Agreement • May 5th, 2014 • Pfenex Inc. • Pharmaceutical preparations • Michigan
This Technology Assignment Agreement (the “Agreement”) is effective as of the Effective Date and is by and between Dow Global Technologies Inc. and The Dow Chemical Company (hereinafter both are referred to as “Dow”), both Delaware corporations having their principal offices at either 2040 Dow Center, Midland, MI, 48674 USA or 2030 Dow Center, Midland, MI, 48674 USA and Pfenex Inc., a Delaware corporation (hereinafter “Pfenex”) having a principal place of business at 5501 Oberlin Drive, San Diego, CA, 92121.
TECHNOLOGY LICENSING AGREEMENTTechnology Licensing Agreement • May 5th, 2014 • Pfenex Inc. • Pharmaceutical preparations • New York
This Technology Licensing Agreement (“Agreement”) is effective as of the Effective Date and is by and between Dow Global Technologies Inc. and/or The Dow Chemical Company (hereinafter both are referred to as “Dow”), both Delaware corporations having their principal offices at either 2040 Dow Center, Midland, MI, 48674 USA or 2030 Dow Center, Midland, MI, 48674 USA and Pfenex Inc., a Delaware corporation (hereinafter “Pfenex”) having a principal place of business at 5501 Oberlin Drive, San Diego, CA.
SECURITY AGREEMENT (Financial Assets)Security Agreement • May 5th, 2014 • Pfenex Inc. • Pharmaceutical preparations • California
GRANT OF SECURITY INTEREST. For valuable consideration, the undersigned PFENEX INC., OF any of them (“Debtor”), hereby grants and transfers to WELLS FARGO BANK, NATIONAL ASSOCIATION, a national banking association having Commercial Banking offices at 401 B. Street, Suite 2201, San Diego, CA 92101 (“Bank”), a security interest in: (a) Debtor’s account no.(s): 3BA05753 maintained at Wells Fargo Institutional Securities, LLC (whether held in Debtor’s name or as a Bank collateral account for the benefit of Debtor), any sub-account thereunder or consolidated therewith, and all replacements or substitutions therefor, including any account resulting from a renumbering or other administrative re-identification thereof (such accounts each and collectively being, the “Securities Account”, and the parties at which the Securities Accounts are maintained each and collectively being, the “Intermediary”), (b) all financial assets credited to the Securities Account (including, without limitation, any
AWARD/CONTRACT 1. THIS CONTRACT IS A RATED ORDER UNDER DPAS (15 CFR 350) u RATING N/A PAGE OF PAGESAward/Contract • May 5th, 2014 • Pfenex Inc. • Pharmaceutical preparations
The purpose of the contract is to further develop a strain and process to manufacture recombinant protective antigen (rPA) for use in anthrax vaccine development using a microbial system.
AMENDED AND RESTATED SUBSCRIPTION AGREEMENTSubscription Agreement • May 5th, 2014 • Pfenex Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED SUBSCRIPTION AGREEMENT, is dated as of May 2, 2014 (this “Agreement”), by and between the investor signatories hereto (each, an “Investor” and together, the “Investors”) and Pfenex Inc., a Delaware corporation (the “Company”).
BRS-TUSTIN SAFEGUARD ASSOCIATES II, LLC Multi Tenant Industrial/Commercial Lease (Net) Between BRS-TUS7TN SAFEGUARD ASSOCIATES II, LLC, a Delaware limited liability company (LESSOR) and PFEIVEX INC, a Delaware corporation (LESSEE) Date: June 22, 2010Attornment Agreement • May 5th, 2014 • Pfenex Inc. • Pharmaceutical preparations
JOINT DEVELOPMENT & LICENSE AGREEMENTJoint Development & License Agreement • May 5th, 2014 • Pfenex Inc. • Pharmaceutical preparations • England and Wales
This Joint Development and License Agreement (this “Agreement”) is made as of the 31st day of December 2012 (the “Effective Date”), by and between Pfenex, Inc., a Delaware corporation with a principal place of business located at 10790 Roselle Street, San Diego, CA 92121 (“Pfenex”), and Agila Biotech Private Limited, company incorporated under the Companies Act, 1956 and having its registered office at Strides House, Bilekahalli, Bannerghatta Road, Bangalore 560 076, India (“Agila”). Pfenex and Agila may be referred to individually as a “Party” or together as the “Parties.”
CONTRIBUTION, ASSIGNMENT AND ASSUMPTION AGREEMENT by and among THE DOW CHEMICAL COMPANY, DOW GLOBAL TECHNOLOGIES INC. and PFENEX INC. NOVEMBER 30, 2009Contribution, Assignment and Assumption Agreement • May 5th, 2014 • Pfenex Inc. • Pharmaceutical preparations • Michigan
THIS CONTRIBUTION, ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Agreement”) is effective as of this 30th day of November 2009 (the “Effective Date”) by and among The Dow Chemical Company, a Delaware corporation (“TDCC”), Dow Global Technologies Inc., a Delaware corporation (“DGTI”) and Pfenex Inc., a Delaware corporation (the “Company”). TDCC, DGTI and the Company are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” TDCC and DGTI are sometimes referred to herein as “Dow.”
